Accessibility Menu
 
Trevi Therapeutics logo

Trevi Therapeutics

(NASDAQ) TRVI

Current Price$10.59
Market Cap$1.36B
Since IPO (2019)+34%
5 Year+286%
1 Year+61%
1 Month+4%

Trevi Therapeutics Financials at a Glance

Market Cap

$1.36B

Revenue (TTM)

$0.00

Net Income (TTM)

$42.76M

EPS (TTM)

$-0.32

P/E Ratio

-33.07

Dividend

$0.00

Beta (Volatility)

0.77 (Low)

Price

$10.59

Volume

30,998

Open

$10.86

Previous Close

$10.59

Daily Range

$10.37 - $11.09

52-Week Range

$4.85 - $14.39

TRVI News

No articles available.

TRVI: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Trevi Therapeutics

Industry

Pharmaceuticals

Employees

34

CEO

Jennifer L. Good, CPA

Headquarters

New Haven, CT 06510, US

TRVI Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-30%

Return on Capital

-27%

Return on Assets

-22%

Earnings Yield

-3.02%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.36B

Shares Outstanding

128.40M

Volume

31.00K

Short Interest

0.00%

Avg. Volume

1.36M

Financials (TTM)

Gross Profit

$132.00K

Operating Income

$49.33M

EBITDA

$49.33M

Operating Cash Flow

$42.09M

Capital Expenditure

$12.00K

Free Cash Flow

$42.10M

Cash & ST Invst.

$188.26M

Total Debt

$753.00K

Trevi Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$0.00

N/A

Gross Profit

$31.00K

+18.4%

Gross Margin

0.00%

N/A

Market Cap

$1.36B

N/A

Market Cap/Employee

$43.94M

N/A

Employees

31

N/A

Net Income

$8.32M

+27.1%

EBITDA

$10.19M

+10.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$187.51M

+75.9%

Accounts Receivable

$986.00K

+85.3%

Inventory

$0.00

N/A

Long Term Debt

$446.00K

-40.3%

Short Term Debt

$307.00K

+7.7%

Return on Assets

-22.10%

N/A

Return on Invested Capital

-26.85%

N/A

Free Cash Flow

$5.85M

+161.2%

Operating Cash Flow

$7.63M

+20.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
ARDXArdelyx, Inc.
$5.31-3.45%
TRMLTourmaline Bio, Inc.
$47.98+0.00%
NVAXNovavax, Inc.
$9.62-1.23%
ORICORIC Pharmaceuticals, Inc.
$11.16+0.54%

Trending Stocks

Symbol / CompanyPricePrice Chg
CMCSAComcast
$29.02+0.00%
NVDANvidia
$172.70-0.03%
INTCIntel
$43.87-0.05%
TQQQProShares Trust - ProShares UltraPro Qqq
$43.08-0.06%

Questions About TRVI

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.